Filing of Pre-Issue Advertisement pursuant to the proposed Rights Issue of Equity Shares of Remedium Lifecare Limited
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty Microcap 250 and 3.2 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Remedium Lifecare Limited (formerly Roxy Exports Limited) is launching a rights issue of up to 49,19,04,000 fully paid-up equity shares of face value Rs. 2 each at a price of Rs. 2 per share (issued at par, not at a premium), for an aggregate amount not exceeding Rs. 4,919.04 lakhs. Eligible shareholders as on the record date of April 15, 2025 will get 61 rights shares for every 50 shares held. The issue opens on April 30, 2025, with on-market renunciations closing May 9, 2025 and issue closing on May 14, 2025. The company has published pre-issue advertisements in Business Standard, Jansatta and Mumbai Lakshadeep as required under SEBI ICDR Regulations. RBL Bank is the banker to the issue and Bigshare Services is the registrar.
Shareholders on record as of April 15, 2025 can subscribe to maintain their proportional holding at face value with no premium; however, the large 61:50 ratio means a significant expansion of share count, which may dilute existing holders who do not participate and could pressure the stock price once rights entitlements trade separately.